Development of a Novel Multi-Isoform ALDH Inhibitor Effective as an Antimelanoma Agent.

ABSTRACT: The aldehyde dehydrogenases (ALDH) are a major family of detoxifying enzymes that contribute to cancer progression and therapy resistance. ALDH overexpression is associated with a poor prognosis in many cancer types. The use of multi-ALDH isoform or isoform-specific ALDH inhibitors as anticancer agents is currently hindered by the lack of viable candidates. Most multi-ALDH isoform inhibitors lack bioavailability and are nonspecific or toxic, whereas most isoform-specific inhibitors are not effective as monotherapy due to the overlapping functions of ALDH family members. The present study details the development of a novel, potent, multi-isoform ALDH inhibitor, called KS100. The rationale for drug development was that inhibition of multiple ALDH isoforms might be more efficacious for cancer

SUBMITTER: Dinavahi SS 

PROVIDER: S-EPMC10763724 | biostudies-literature | 2020 Feb

REPOSITORIES: biostudies-literature